Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Asset Writedowns and Impairment (2024 - 2025)

Historic Asset Writedowns and Impairment for Indivior Pharmaceuticals (INDV) over the last 2 years, with Q3 2025 value amounting to $16.0 million.

  • Indivior Pharmaceuticals' Asset Writedowns and Impairment changed N/A to $16.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.0 million, marking a year-over-year change of. This contributed to the annual value of $8.0 million for FY2024, which is N/A changed from last year.
  • Indivior Pharmaceuticals' Asset Writedowns and Impairment amounted to $16.0 million in Q3 2025.
  • Indivior Pharmaceuticals' Asset Writedowns and Impairment's 5-year high stood at $16.0 million during Q3 2025, with a 5-year trough of $1.0 million in Q1 2024.